Global vaccine-assessment network
- October 5, 2020
- Posted by: OptimizeIAS Team
- Category: DPN Topics
No Comments
Subject: IR
Context:
Coalition for Epidemic Preparedness Innovations (CEPI) has announced a central global network of laboratories
Concept:
- It helps to assess and compare immunological responses generated by the Covid-19 vaccine candidates.
- To establish this global vaccine-assessment network, CEPI has announced partnerships with five clinical sample testing laboratories that included India’s Translational Health Sciences and Technological Institute (THSTI).
- The network will use the same testing reagents originating in the labs of Nexelis and PHE and follow common protocols to measure the immunogenicity of multiple Covid-19 vaccine candidates
- This approach will ensure uniformity in assessment and informed identification of the most promising vaccine candidates. CEPI is actively negotiating with additional laboratories to participate in this network
- Currently there are wide range of Covid-19 vaccine approaches and technologies deployed (eg, recombinant viral vectors, live attenuated vaccines, recombinant proteins and nucleic acids), standard evaluation of the true potential of these vaccine formulations becomes very complex.
- Through centralising the analysis of samples obtained from trials of Covid-19 vaccine candidates, the new clinical-sample-testing network will minimise variation in results obtained, which could otherwise arise due to such technical differences when carrying out independent analysis.